JP2009518306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518306A5 JP2009518306A5 JP2008543528A JP2008543528A JP2009518306A5 JP 2009518306 A5 JP2009518306 A5 JP 2009518306A5 JP 2008543528 A JP2008543528 A JP 2008543528A JP 2008543528 A JP2008543528 A JP 2008543528A JP 2009518306 A5 JP2009518306 A5 JP 2009518306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- antigen
- suspension
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 54
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 239000002105 nanoparticle Substances 0.000 claims 18
- 239000000725 suspension Substances 0.000 claims 13
- 230000028993 immune response Effects 0.000 claims 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 5
- 239000002577 cryoprotective agent Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 244000052769 pathogen Species 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 5
- 229920002988 biodegradable polymer Polymers 0.000 claims 4
- 239000004621 biodegradable polymer Substances 0.000 claims 4
- 238000004108 freeze drying Methods 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical group 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical group BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 230000029662 T-helper 1 type immune response Effects 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000001571 immunoadjuvant effect Effects 0.000 claims 1
- 239000000568 immunological adjuvant Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229940065514 poly(lactide) Drugs 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920002721 polycyanoacrylate Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74186005P | 2005-12-02 | 2005-12-02 | |
| US60/741,860 | 2005-12-02 | ||
| US77526506P | 2006-02-21 | 2006-02-21 | |
| US60/775,265 | 2006-02-21 | ||
| PCT/US2006/046212 WO2008051245A2 (en) | 2005-12-02 | 2006-12-01 | Nanoparticles for use in immunogenic compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168462A Division JP2013227354A (ja) | 2005-12-02 | 2013-08-14 | 免疫原性組成物で使用するためのナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009518306A JP2009518306A (ja) | 2009-05-07 |
| JP2009518306A5 true JP2009518306A5 (enExample) | 2011-01-06 |
| JP5806444B2 JP5806444B2 (ja) | 2015-11-10 |
Family
ID=39204901
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543528A Expired - Fee Related JP5806444B2 (ja) | 2005-12-02 | 2006-12-01 | 免疫原性組成物で使用するためのナノ粒子 |
| JP2013168462A Pending JP2013227354A (ja) | 2005-12-02 | 2013-08-14 | 免疫原性組成物で使用するためのナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168462A Pending JP2013227354A (ja) | 2005-12-02 | 2013-08-14 | 免疫原性組成物で使用するためのナノ粒子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9393215B2 (enExample) |
| EP (1) | EP1954252B1 (enExample) |
| JP (2) | JP5806444B2 (enExample) |
| CA (1) | CA2631714C (enExample) |
| ES (1) | ES2564241T3 (enExample) |
| WO (1) | WO2008051245A2 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR011700A0 (en) * | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| CA2606349C (en) | 2005-01-28 | 2019-03-05 | Galen Bio, Inc. | Immunologically active compositions |
| EP1954252B1 (en) | 2005-12-02 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Nanoparticles for use in immunogenic compositions |
| US20090068114A1 (en) * | 2007-09-07 | 2009-03-12 | Yousef Haik | Noninvasive Thermometry Monitoring System |
| CA2722765C (en) * | 2008-04-28 | 2016-10-04 | Novartis Ag | Nanoparticles for use in pharmaceutical compositions |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| JP2012501966A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法 |
| EP3725328A3 (en) * | 2008-06-27 | 2020-12-23 | Zoetis Services LLC | Novel adjuvant compositions |
| WO2010017330A1 (en) * | 2008-08-06 | 2010-02-11 | Novartis Ag | Microparticles for use in immunogenic compositions |
| ES2776126T3 (es) | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
| JP6282395B2 (ja) | 2009-05-27 | 2018-02-21 | セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 異なる放出速度の構成要素を有するナノキャリア |
| TR201802380T4 (tr) | 2009-06-10 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Benzonaftiridin içeren aşılar. |
| CN102811743B (zh) | 2009-12-11 | 2015-11-25 | 佰恩德治疗股份有限公司 | 冻干治疗颗粒的稳定制剂 |
| EA201290499A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами |
| ES2543795T3 (es) | 2010-03-31 | 2015-08-21 | Stabilitech Ltd. | Estabilización de partículas virales |
| JP6023696B2 (ja) | 2010-03-31 | 2016-11-09 | スタビリテック リミテッド | ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法 |
| US20130164296A1 (en) | 2010-03-31 | 2013-06-27 | Jeffrey Drew | Excipients for Stabilising Viral Particles, Polypeptides or Biological Material |
| NO2575876T3 (enExample) | 2010-05-26 | 2018-05-05 | ||
| KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| PT2594140T (pt) | 2010-07-16 | 2019-06-11 | Centro Nac De Tecnologia Y Seguridad Alimentaria Laboratorio Dei Ebro | Nanopartículas para encapsulamento de compostos, sua produção e utilizações |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| WO2012024621A2 (en) * | 2010-08-20 | 2012-02-23 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin |
| DK2609931T3 (da) | 2010-08-26 | 2020-12-07 | Toray Industries | Immunogen sammensætning |
| HUE061068T2 (hu) | 2010-08-31 | 2023-05-28 | Glaxosmithkline Biologicals Sa | Pegilált liposzómák immunogént kódoló RNS szállítására |
| CN103429606A (zh) | 2010-10-01 | 2013-12-04 | 现代治疗公司 | 设计核酸及其使用方法 |
| EP4098324A1 (en) * | 2010-10-11 | 2022-12-07 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| RU2013131795A (ru) * | 2010-12-10 | 2015-01-20 | Мерк Шарп Энд Домэ Корп. | Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций |
| KR101820026B1 (ko) | 2011-01-04 | 2018-01-18 | 알치벨 팔마, 에스.엘. | 결핵을 치료하거나 예방하는데 적합한 리포솜 제형 |
| US10286056B2 (en) * | 2011-01-27 | 2019-05-14 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with crystallisation inhibitors |
| AU2012212264B2 (en) * | 2011-01-31 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| CN103458879A (zh) * | 2011-03-25 | 2013-12-18 | 西莱克塔生物科技公司 | 渗透性介导释放型合成纳米载体 |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US20140038996A1 (en) | 2011-04-15 | 2014-02-06 | Janssen Pharmaceutica Nv | Freeze Dried Drug Nanosuspensions |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| US20130039954A1 (en) | 2011-07-29 | 2013-02-14 | Selecta Biosciences, Inc. | Control of antibody responses to synthetic nanocarriers |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| KR20190099538A (ko) | 2011-10-03 | 2019-08-27 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도 |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| IN2014MN01594A (enExample) | 2012-01-12 | 2015-05-08 | Archivel Farma Sl | |
| ES2765035T3 (es) | 2012-01-20 | 2020-06-05 | South Dakota State Univ | Formulaciones de inulina y de acetato de inulina |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| AU2013243954A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| US9546361B2 (en) | 2012-10-12 | 2017-01-17 | Lehigh University | Thermally stable enzymes, compositions thereof and methods of using same |
| DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
| FI20126281L (fi) * | 2012-12-10 | 2014-06-11 | Filana Ltd Oy | Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| DK3065771T3 (da) | 2013-11-04 | 2019-06-11 | Uti Lp | Fremgangsmåder og sammensætninger til vedvarende immunterapi |
| US10881720B2 (en) * | 2014-01-30 | 2021-01-05 | The Board Of Regents Of The University Of Texas System | Nanoparticles for immune stimulation |
| ES2834927T3 (es) | 2014-03-14 | 2021-06-21 | Pfizer | Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| PT3981437T (pt) | 2014-04-23 | 2025-01-15 | Modernatx Inc | Vacinas de ácidos nucleicos |
| US9814769B2 (en) | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
| KR102859521B1 (ko) | 2015-05-06 | 2025-09-12 | 유티아이 리미티드 파트너쉽 | 지속 치료를 위한 나노입자 조성물 |
| CN114617959A (zh) | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
| WO2017123652A1 (en) | 2016-01-11 | 2017-07-20 | Verndari, Inc. | Microneedle compositions and methods of using same |
| EP3432868B1 (en) * | 2016-03-23 | 2020-12-16 | Academia Sinica | Thin-shell polymeric nanoparticles and uses thereof |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| WO2019023196A1 (en) | 2017-07-24 | 2019-01-31 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE |
| CA3083748A1 (en) | 2017-11-29 | 2019-06-06 | Uti Limited Partnership | Methods of treating autoimmune disease |
| US11278612B2 (en) | 2018-03-19 | 2022-03-22 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
| ES2960936T3 (es) * | 2018-04-25 | 2024-03-07 | Ethris Gmbh | Formulaciones a base de lípidos para el suministro de ARN |
| US10874737B2 (en) | 2018-06-01 | 2020-12-29 | Iowa State University Research Foundation, Inc. | Influenza nanovaccine |
| KR102442103B1 (ko) * | 2019-04-30 | 2022-09-08 | 주식회사 엘지화학 | 캐스파제 저해제의 프로드럭 |
| JP7704740B2 (ja) | 2019-09-16 | 2025-07-08 | アムジエン・インコーポレーテツド | 薬物送達デバイスの外部滅菌の方法 |
| WO2023048758A1 (en) * | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Dried nanoparticle compositions |
| US12064511B2 (en) | 2022-03-24 | 2024-08-20 | The Regents Of The University Of California | Lipid nanoparticles containing silyl lipids for use in vaccines and gene therapy |
| CN119136792A (zh) | 2022-03-30 | 2024-12-13 | 赢创运营有限公司 | 用于将多核苷酸递送至细胞中的由阳离子脂质和聚(乳酸-共-羟基乙酸)组成的配制物 |
| KR20250154451A (ko) * | 2023-02-28 | 2025-10-28 | 도요보 가부시키가이샤 | 3-히드록시부티르산 탈수소 효소 건조 제제 |
| WO2024215719A2 (en) * | 2023-04-10 | 2024-10-17 | Academia Sinica | Composition, vaccine and method for treating influenza a |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
| FR2608988B1 (fr) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
| FR2634397B2 (fr) | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules |
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| AU4755696A (en) | 1995-01-05 | 1996-07-24 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Surface-modified nanoparticles and method of making and using same |
| US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| GB9514285D0 (en) | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
| FR2742357B1 (fr) * | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
| US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| CN1246778A (zh) * | 1997-02-07 | 2000-03-08 | 扇形支撑剑桥有限公司 | 用于制备干的、贮存稳定的血小板的方法和组合物 |
| IL138306A0 (en) | 1998-03-13 | 2001-10-31 | American Home Prod | Polynucleotide composition, method of preparation and use thereof |
| ATE321535T1 (de) | 1998-07-29 | 2006-04-15 | Chiron Corp | Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung |
| DE60125795T2 (de) | 2000-09-28 | 2007-10-18 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung |
| ES2260291T3 (es) | 2000-09-28 | 2006-11-01 | Chiron Corporation | Microparticulas para la administracion de acidos nucleicos heterologos. |
| DE10214031A1 (de) * | 2002-03-27 | 2004-02-19 | Pharmatech Gmbh | Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation |
| HUE057124T2 (hu) | 2002-05-02 | 2022-04-28 | Wyeth Holdings Llc | Calicheamicin származék - hordozó konjugátumok |
| EP2181595A1 (en) * | 2002-08-16 | 2010-05-05 | Yeda Research And Development Company Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| JP2006501936A (ja) | 2002-10-04 | 2006-01-19 | エラン ファーマ インターナショナル，リミティド | 固体ナノ粒子活性薬剤のガンマ線照射 |
| JP2006520746A (ja) * | 2002-12-27 | 2006-09-14 | カイロン コーポレイション | リン脂質を含む免疫原性組成物 |
| AU2004314706A1 (en) * | 2003-12-11 | 2005-08-11 | University Of Miami | Immunotherapy compositions, method of making and method of use thereof |
| EP1954252B1 (en) | 2005-12-02 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Nanoparticles for use in immunogenic compositions |
-
2006
- 2006-12-01 EP EP06851781.2A patent/EP1954252B1/en active Active
- 2006-12-01 ES ES06851781.2T patent/ES2564241T3/es active Active
- 2006-12-01 WO PCT/US2006/046212 patent/WO2008051245A2/en not_active Ceased
- 2006-12-01 CA CA2631714A patent/CA2631714C/en not_active Expired - Fee Related
- 2006-12-01 JP JP2008543528A patent/JP5806444B2/ja not_active Expired - Fee Related
- 2006-12-01 US US12/095,655 patent/US9393215B2/en active Active
-
2013
- 2013-08-14 JP JP2013168462A patent/JP2013227354A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518306A5 (enExample) | ||
| He et al. | Advances in aluminum hydroxide-based adjuvant research and its mechanism | |
| JP2006526649A5 (enExample) | ||
| Lebre et al. | Modulation of immune responses by particulate materials | |
| Zhou et al. | Biomimetic nanotechnology toward personalized vaccines | |
| Genito et al. | Considerations for size, surface charge, polymer degradation, co‐delivery, and manufacturability in the development of polymeric particle vaccines for infectious diseases | |
| Sun et al. | Nanomaterial-based vaccine adjuvants | |
| CA2528007A1 (en) | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen | |
| Islam et al. | Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review | |
| KR20230093248A (ko) | 전 세포 성분이 로딩된 표적 수송 시스템 및 이의 용도 | |
| Powell et al. | Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes | |
| Köping-Höggård et al. | Nanoparticles as carriers for nasal vaccine delivery | |
| Subbiah et al. | N, N, N-Trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen | |
| CN114225021B (zh) | 基于一种或多种癌细胞和/或肿瘤组织全细胞组分或其混合物的预防或治疗癌症的疫苗系统 | |
| Sokolova et al. | The potential of nanoparticles for the immunization against viral infections | |
| JP2009527572A5 (enExample) | ||
| Kumari et al. | Biomaterials-based formulations and surfaces to combat viral infectious diseases | |
| Goyal et al. | Aquasomes—a nanoparticulate approach for the delivery of antigen | |
| CN114288397B (zh) | 基于多种癌细胞和/或肿瘤组织全细胞组分的预防或治疗癌症的疫苗系统及其制备与应用 | |
| Schully et al. | Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis | |
| JP2011506334A5 (enExample) | ||
| KR20200038339A (ko) | 다가 vlp 접합체 | |
| Yoon et al. | Enhanced efficacy of immunization with a foot-and-mouth disease multi-epitope subunit vaccine using mannan-decorated inulin microparticles | |
| JP2008507590A (ja) | 免疫活性剤を経皮送達するための方法及び配合物 | |
| CN105363029A (zh) | 一种关于hpv病毒的新型佐剂疫苗组合物 |